Continuous glucose monitor

Supersapiens Closes $13.5 Million in Early-Stage Funding

Retrieved on: 
Tuesday, April 27, 2021
Medicine, Articles, Medical monitoring, Continuous glucose monitor, CGM, Blood glucose monitoring, Glucose, Clinical medicine, Startup company

b'ATLANTA, April 27, 2021 /PRNewswire/ -- Supersapiens announces a $13.5 million capital raise led by MICA Ventures AG.

Key Points: 
  • b'ATLANTA, April 27, 2021 /PRNewswire/ -- Supersapiens announces a $13.5 million capital raise led by MICA Ventures AG.
  • Supersapiens also attracted global investment from CM Ventures, Rubix Ventures, Swiss Startup Group, and Wahoo Fitness.\n"Sports continuous glucose monitoring (CGM) is an absolute game changer for all athletes.
  • As an athlete, I am intimately aware of the impact glucose has on the ability to achieve your goals.
  • For markets where Supersapiens has yet to be released, athletes can secure their spot on the waitlist .

GlucoModicum’s non-invasive glucose monitoring technology performs 13x better than previous needle-free approaches

Retrieved on: 
Tuesday, April 20, 2021
Medicine, Clinical medicine, Branches of biology, Diabetes, Chemical pathology, Medical monitoring, Blood tests, Biotechnology, Blood glucose monitoring, Diabetes management, Continuous glucose monitor, Blood sugar level

There is therefore a strong need for the development of a non-invasive glucose sensor and continuous glucose monitoring devices.\nHowever, high quality, non-invasive sampling of interstitial fluid has been the missing piece of the puzzle in enabling accurate needle-free glucose monitoring by wearable devices.

Key Points: 
  • There is therefore a strong need for the development of a non-invasive glucose sensor and continuous glucose monitoring devices.\nHowever, high quality, non-invasive sampling of interstitial fluid has been the missing piece of the puzzle in enabling accurate needle-free glucose monitoring by wearable devices.
  • This approach to measuring glucose levels is non-invasive and would offer a solution that is gentle on the skin, whilst enabling needle-free and continuous glucose monitoring, delivering rapid and accurate results.
  • Alejandro Garc\xc3\xada, Chief Technology Officer at GlucoModicum, said: \xe2\x80\x9cThese results confirm the validity of our technology for noninvasive biomarker monitoring.
  • Wearable devices for continuous self-monitoring of glucose can play a crucial role in both the prevention and management of diabetes.

Global Implantable Sensor Market Forecast to 2027 - COVID-19 Impact and Analysis - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 15, 2021
Medical devices, Health, Medicine, Clinical medicine, Health, Medical monitoring, Blood glucose monitoring, Continuous glucose monitor, Oxygen sensor, Diabetes, GlySens ICGM

b'The "Implantable Sensor Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Type; Application; End User, and Geography" report has been added to ResearchAndMarkets.com\'s offering.\nAccording to this report the implantable sensor market was valued at US$ 4,912.00 million in 2019 and it is projected to reach US$ 11,415.62 million by 2027; it is expected to grow at a CAGR of 11.1% during 2020-2027.

Key Points: 
  • b'The "Implantable Sensor Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Type; Application; End User, and Geography" report has been added to ResearchAndMarkets.com\'s offering.\nAccording to this report the implantable sensor market was valued at US$ 4,912.00 million in 2019 and it is projected to reach US$ 11,415.62 million by 2027; it is expected to grow at a CAGR of 11.1% during 2020-2027.
  • The report highlights trends prevailing in the global implantable sensor market, and the factors driving and restraining the market growth.\nBased on type, the global implantable sensor market is segmented into glucose sensor, temperature sensor, oxygen sensor, pressure sensor, and others.
  • In 2019, the glucose sensor segment accounted for the highest share of the market.
  • The growth for this segment is attributed to growing cases of diabetes coupled with increasing adoption of continuous glucose monitoring (CGM) devices.\nThe growth of the implantable sensor market is driven by increasing prevalence of chronic diseases and growing adoption of mobile healthcare technologies.

Exyte to build Dexcom's first manufacturing facility in Asia

Retrieved on: 
Thursday, April 15, 2021
Medical technology, Dexcom, Continuous glucose monitor, Batu Kawan, Penang

This is the first manufacturing facility for the U.S.-based diabetes care technology provider outside the United States.\nExyte is proud to support Dexcom\'s strategic growth plans as it expands manufacturing into Asia for the first time.

Key Points: 
  • This is the first manufacturing facility for the U.S.-based diabetes care technology provider outside the United States.\nExyte is proud to support Dexcom\'s strategic growth plans as it expands manufacturing into Asia for the first time.
  • Located in Batu Kawan, Penang, and with 1.8 million square feet of gross floor area, the project will house a manufacturing facility for continuous glucose monitoring (CGM) systems.
  • Exyte has a truly global footprint, serving the most technically demanding clients in markets such as semiconductors, batteries, pharmaceuticals, biotechnology, and data centers.
  • The company is ideally positioned to further strengthen its market leadership with its broad industry insight and its exceptional talents.\n'

Exyte to build Dexcom's first manufacturing facility in Asia

Retrieved on: 
Thursday, April 15, 2021
Medical technology, Dexcom, Continuous glucose monitor, Batu Kawan, Penang

This is the first manufacturing facility for the U.S.-based diabetes care technology provider outside the United States.\nExyte is proud to support Dexcom\'s strategic growth plans as it expands manufacturing into Asia for the first time.

Key Points: 
  • This is the first manufacturing facility for the U.S.-based diabetes care technology provider outside the United States.\nExyte is proud to support Dexcom\'s strategic growth plans as it expands manufacturing into Asia for the first time.
  • Located in Batu Kawan, Penang, and with 1.8 million square feet of gross floor area, the project will house a manufacturing facility for continuous glucose monitoring (CGM) systems.
  • Exyte has a truly global footprint, serving the most technically demanding clients in markets such as semiconductors, batteries, pharmaceuticals, biotechnology, and data centers.
  • The company is ideally positioned to further strengthen its market leadership with its broad industry insight and its exceptional talents.\n'

BRIC Continuous Glucose Monitoring (CGM) Devices Market Report 2020-2025: Users, Reimbursement Policy, CGM Components (Glucose Sensor, Transmitter), Diabetes (Type 1 & 2) Population, & Forecasts

Retrieved on: 
Wednesday, April 14, 2021
Foreign relations, International relations, Foreign relations of Brazil, Foreign relations of China, Foreign relations of India, Government, Medical monitoring, Continuous glucose monitor, Bric, Blood glucose monitoring, Bric, CGM

b'DUBLIN, April 14, 2021 /PRNewswire/ -- The "BRIC CGM Market, Users, Reimbursement Policy, CGM Components (Glucose Sensor, Transmitter), Diabetes (Type1 & 2) Population, & Forecast" report has been added to ResearchAndMarkets.com\'s offering.\nBRIC CGM market will be US$ 870 Million by the end of the year 2025.\nThe BRIC CGM market witnessed strong growth in recent decades and is further expected to grow primarily due to the increasing adaptation of continuous glucose monitoring devices in China and India.\nThis rising diabetic population in Brazil, Russia, India, and China and increasing the adoption of CGM devices and Continuous Positive Cost-Effective Analysis by BRIC Countries will propel the growth of the BRIC CGM market.

Key Points: 
  • b'DUBLIN, April 14, 2021 /PRNewswire/ -- The "BRIC CGM Market, Users, Reimbursement Policy, CGM Components (Glucose Sensor, Transmitter), Diabetes (Type1 & 2) Population, & Forecast" report has been added to ResearchAndMarkets.com\'s offering.\nBRIC CGM market will be US$ 870 Million by the end of the year 2025.\nThe BRIC CGM market witnessed strong growth in recent decades and is further expected to grow primarily due to the increasing adaptation of continuous glucose monitoring devices in China and India.\nThis rising diabetic population in Brazil, Russia, India, and China and increasing the adoption of CGM devices and Continuous Positive Cost-Effective Analysis by BRIC Countries will propel the growth of the BRIC CGM market.
  • China has the largest market share in 2019; while, India is foreseen to witness a significant market share during the forecast period.\nThe BRIC CGM market is driven mainly by the increasing numbers of people with diabetes across BRIC countries, growing diabetes research, and increasing international research collaborations.\nThe Continuous Positive Cost-Effective Analysis by BRICS Countries and rapid urbanization and CGM Technology Convenient for both Patients & Physicians are further expected to contribute to the growth of this CGM market.\nHowever, Controversy regarding Clinical Benefits and the high cost of diabetes care devices are the remonstrance growth of this market.\nIn the year Feb 2019, Senseonics made a distribution agreement with Roche Diabetes Care for two years, giving exclusive rights to the Big Biotech for selling implantable glucose monitoring systems in Brazil, Russia, India, and China.\nThe continuous glucose monitoring (CGM) devices market in BRIC countries are set to thrive regardless of the major upheaval caused by the COVID-19 pandemic.\nThe surging demand for CGM in BRIC countries are primarily driven by a growing awareness of the devices and companies\' quick responses to the COVID-19 epidemic.\n'

Dexcom Starts Direct Distribution in the Netherlands

Retrieved on: 
Wednesday, April 7, 2021
Diabetes, Health, Medical devices, Medical technology, Dexcom, Medicine, Continuous glucose monitor, Medical monitoring, Blood glucose monitoring, CGM

DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today it has ended its distribution collaboration with Zkope Healthcare and is now selling the Dexcom G6 CGM system directly throughout the Netherlands.

Key Points: 
  • DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today it has ended its distribution collaboration with Zkope Healthcare and is now selling the Dexcom G6 CGM system directly throughout the Netherlands.
  • At Dexcom, we are committed to expanding access to CGM for people with diabetes around the world.
  • To learn more about Dexcom G6, visit www.dexcom.com or contact customer support by phone at 08000 201 985.
  • 2021 Dexcom, Inc. Dexcom, Dexcom G6 and Dexcom Follow are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries.

Blood Glucose Monitoring Consumables Market Size to Reach Revenues of over USD 29 Billion by 2026 - Arizton

Retrieved on: 
Tuesday, April 6, 2021
Medicine, Diabetes, Clinical medicine, Medical technology, Medical monitoring, Blood tests, Continuous glucose monitor, Blood glucose monitoring, Blood sugar level, Glucose, CGM, Glucose meter

CHICAGO, April 6, 2021 /PRNewswire/ -- In-depth analysis and data-driven insights on the impact of COVID-19 included in this global blood glucose monitoring consumables market report.

Key Points: 
  • CHICAGO, April 6, 2021 /PRNewswire/ -- In-depth analysis and data-driven insights on the impact of COVID-19 included in this global blood glucose monitoring consumables market report.
  • The blood glucose monitoring consumables market is expected to grow at a CAGR of around 13% during the period 20202026.
  • The usage of continuous glucose monitoring (CGM) devices is high among the patients in the long-term care.
  • Market Segmentation A detailed analysis by products, end-users, distribution channel, and geography
    Test strips accounted for over 64% of the global blood glucose monitoring consumables market in 2020.

Blood Glucose Monitoring Consumables Market Size to Reach Revenues of over USD 29 Billion by 2026 - Arizton

Retrieved on: 
Tuesday, April 6, 2021
Medicine, Diabetes, Clinical medicine, Medical technology, Medical monitoring, Blood tests, Continuous glucose monitor, Blood glucose monitoring, Blood sugar level, Glucose, CGM, Glucose meter

CHICAGO, April 6, 2021 /PRNewswire/ -- In-depth analysis and data-driven insights on the impact of COVID-19 included in this global blood glucose monitoring consumables market report.

Key Points: 
  • CHICAGO, April 6, 2021 /PRNewswire/ -- In-depth analysis and data-driven insights on the impact of COVID-19 included in this global blood glucose monitoring consumables market report.
  • The blood glucose monitoring consumables market is expected to grow at a CAGR of around 13% during the period 20202026.
  • The usage of continuous glucose monitoring (CGM) devices is high among the patients in the long-term care.
  • Market Segmentation A detailed analysis by products, end-users, distribution channel, and geography
    Test strips accounted for over 64% of the global blood glucose monitoring consumables market in 2020.

Welldoc and Dexcom Expand Strategic Partnership to Integrate Platforms and Offer Integrated Type 2 Diabetes Management Solution

Retrieved on: 
Monday, April 5, 2021
Medical devices, Health, Diabetes, Fitness & Nutrition, Managed care, Pharmaceutical, Dexcom, Medical technology, Medicine, Health, Continuous glucose monitor

Welldoc will offer its BlueStar digital health solution and the Dexcom G6 CGM system as a single platform offering for select employers and health systems, beginning with a Fortune 100 company.

Key Points: 
  • Welldoc will offer its BlueStar digital health solution and the Dexcom G6 CGM system as a single platform offering for select employers and health systems, beginning with a Fortune 100 company.
  • The Dexcom G6 system measures glucose levels just beneath the surface of the skin and sends data wirelessly every five minutes.
  • BlueStar, an FDA-cleared digital health solution, guides individuals through the complicated journey of living with diabetes by enabling them to self-manage their conditions and enhancing connections to their healthcare teams.
  • During the pandemic, we have observed the value of Dexcom CGM for all people with diabetes.